Compare Aehr Test Systems (AEHR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Incyte Corporation — how do they compare? Aehr Test Systems trades at $128.91 (market cap $3.82B), while Incyte Corporation trades at $120.76 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 6.4× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| AEHR | INCY | |
|---|---|---|
Market Cap | $3.82B | $24.54B |
Sector | Technology | Health |
52-Week High | $117.18 | $129.93 |
52-Week Low | $17.38 | $81.61 |
Enterprise Value | $3.72B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems (AEHR) surged 25.02% to $132.77, driven by strong earnings beats and a $22 million follow-on order for AI processor wafer-level burn-in systems (Accesswire, August 12, 2026). The stock exhibits bullish technical signals with support at $112 and resistance at $129, though RSI suggests overbought conditions. Revenue reached $58.97 million in 2025, but net income remained negative at -$3.91 million, reflecting high growth investments.
Outlook is optimistic due to AI and silicon photonics demand, with FY27 revenue growth projected at 160–200% (Seeking Alpha, July 18, 2026). Risks include customer concentration and negative cash flow. Analysts are mixed (33% buy, 67% hold), highlighting valuation concerns at a P/S of 71.87. Upside potential exists if execution aligns with backlog growth.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
